Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.33 |
| ▸ | EED | O75530 | 1/20 | 0.33 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6156218 | 0.93 | PKM (0.48) | PKMLMNAMPOMAPTKMT2A | |
| SCHEMBL17459025 | 0.91 | PKM (0.54) | PKMLMNAMPOMAPTKMT2A | |
| SCHEMBL21964543 | 0.89 | EED (0.43) | PKMLMNAMAPTKMT2AMEN1 | |
| SCHEMBL16985255 | 0.84 | LMNA (0.35) | PKMLMNAALDH1A1EEDRBBP4 | |
| SCHEMBL17458924 | 0.82 | LMNA (0.40) | PKMLMNAMAPTKMT2ARAB9A | |
| SCHEMBL18256013 | 0.81 | CRHR1 (0.46) | PKMLMNAMAPTKMT2AALDH1A1 | |
| SCHEMBL5021295 | 0.78 | PKM (0.43) | PKMLMNAKMT2ACRHR1HDAC1 | |
| SCHEMBL14638402 | 0.74 | — | — | |
| SCHEMBL31319606 | 0.74 | PKM (0.54) | PKMLMNAHDAC1HDAC2ADORA2A | |
| SCHEMBL31319713 | 0.74 | PKM (0.40) | PKMLMNACRHR1HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-04-21 | — | — | US | disclosed |
| US-11214565-B2 | Compound, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180327391-A1 | COMPOUND, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. | 2018-11-15 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327391-A1 | COMPOUND, COMPOSITIONS, AND METHODS | LRRK2, PARK7, MAPT | PKM 232/4885LMNA 410/4885MPO 4062/4885 |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | PKM 761/4885LMNA 3015/4885MPO 3486/4885 |
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | LRRK2, PARK7, SNCA | PKM 234/4885LMNA 429/4885MPO 3998/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | PKM 478/4885LMNA 3243/4885MPO 4086/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | PKM 761/4885LMNA 3015/4885MPO 3486/4885 |
| US-11214565-B2 | Compound, compositions, and methods | LRRK2, PARK7, MAPT | PKM 232/4885LMNA 410/4885MPO 4062/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | PKM 766/4885LMNA 3115/4885MPO 3415/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | PKM 766/4885LMNA 3115/4885MPO 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.